Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08BAW
|
|||
| Former ID |
DNC008229
|
|||
| Drug Name |
Bu-RYYRIK-NH2
|
|||
| Synonyms |
CHEMBL428076
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C46H74N14O8
|
|||
| Canonical SMILES |
CCCC(=O)NC(CCCN=C(N)N)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)NC(CCCN=C(N)N)C(=O)NC(C(C)CC)C(=O)NC(CCCCN)C(=O)N
|
|||
| InChI |
1S/C46H74N14O8/c1-4-13-37(62)55-33(17-11-24-53-45(49)50)40(64)58-35(26-29-14-7-6-8-15-29)43(67)59-36(27-30-19-21-31(61)22-20-30)42(66)57-34(18-12-25-54-46(51)52)41(65)60-38(28(3)5-2)44(68)56-32(39(48)63)16-9-10-23-47/h6-8,14-15,19-22,28,32-36,38,61H,4-5,9-13,16-18,23-27,47H2,1-3H3,(H2,48,63)(H,55,62)(H,56,68)(H,57,66)(H,58,64)(H,59,67)(H,60,65)(H4,49,50,53)(H4,51,52,54)/t28-,32-,33-,34-,35-,36-,38-/m0/s1
|
|||
| InChIKey |
DPJOADTYQPSSOH-LWFLANIVSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nociceptin receptor (OPRL1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.